Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
  • C07D491/14—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

• the invention relates to novel compounds which are used in the pharmaceutical industry as active compounds for the production of medicaments.
• International Patent Application WO 95/27714 discloses certain substituted tricyclic imidazo[1,2-a]pyridines which are said to reversibly inhibit gastric acid secretion and to be useful in the prevention and treatment of gastrointestinal inflammatory diseases.
• International Patent Application WO 98/42707 discloses tetrahydroimidazo[1,2-h][1,7]naphthyridines which shall be suitable for the prevention and treatment of gastrointestinal diseases.
• WO 98/54188 describes fused dihydropyrans, which are said to be suitable for the treatment of peptic ulcer disorders.
• the invention relates to compounds of the formula 1
• R1 is methyl or hydroxymethyl
• one of the substituents R2a and R2b is hydrogen and the other is hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• one of the substituents R3a and R3b is hydrogen and the other is hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• Suitable salts of compounds of the formula 1 are especially all acid addition salts. Particular mention may be made of the pharmacologically tolerable salts of the inorganic and organic acids customarily used in pharmacy. Those suitable are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, where the acids are employed in salt preparation—depending on whether a mono- or polybasic acid, water
• Pharmacologically intolerable salts which can be initially obtained as process products, for example in the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
• the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of formula 1 as well as all solvates and in particular all hydrates of the salts of the compounds of formula 1.
• the compounds of the formula 1 have three chiral centers.
• the invention relates to all eight conceivable stereoisomers In any desired mixing ratio with one another, including the pure enantiomers, which are a preferred subject of the invention.
• a preferred embodiment of the invention are compounds of the formula 1*
• R1 is methyl
• one of the substituents R2a and R2b is hydrogen and the other is hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• one of the substituents R3a and R3b is hydrogen and the other is hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• R2a or R2b on the one hand and R3a or R3b on the other hand are not simultaneously hydroxy
• An embodiment (embodiment a) of the invention are compounds of the formula 1*, in which
• R1 is methyl
• one of the substituents R2a and R2b is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• one of the substituents R3a and R3b is hydrogen and the other is hydroxy
• a further embodiment (embodiment b) of the invention are compounds of the formula 1*, in which
• R1 is methyl
• one of the substituents R2a and R2b is hydrogen and the other is hydroxy
• one of the substituents R3a and R3b is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• a further embodiment (embodiment c) of the invention are compounds of the formula 1* , in which
• R1 is methyl
• one of the substituents R2a and R2b is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• one of the substituents R3a and R3b is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• Preferred compounds of the embodiments a to c are those, in which R3b is hydrogen.
• R3b is hydrogen.
• the absolute configuration “R” for both positions 8 and 9 has been assigned to these compounds of formula 1* in which R3b is hydrogen.
• Particularly preferred compounds of the embodiments a to c are those, in which R2a and R3b are hydrogen.
• Preferred compounds within the scope of the invention are those of embodiment a, which can be characterized by the formula 1**
• one of the substituents Ra and Rb is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy
• Particularly preferred compounds of embodiment a are those of formula 1**, in which
• Ra is hydrogen
• Rb is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,
• the compounds according to the invention can be prepared as described for or starting from the compounds disclosed in International Patent Application WO 98/54188. Alternatively, the compounds according to the invention can be prepared as outlined in the following reaction schemes and/or as described exemplary in the following Examples.
• the above scheme 1 represents an example of an enantioselective synthesis of the diol 6, which is subsequently subjected to etherification as described in more detail below.
• the group X in compound 3 above is a suitable leaving group, e. g. a halogen atom, preferably a chlorine atom.
• the acylation is carried out under usual conditions, preferably with using bis-(trimethylsilyl)-sodium or -potassium amide In case that the leaving group is a chlorine atom.
• the oxidation following the acylation is carried out under conditions which are known to the expert, using for example chloranil, oxygen or manganese dioxide as oxidation agent.
• chloranil, oxygen or manganese dioxide as oxidation agent.
• special conditions have to be used with regard to the auxiliary acid.
• formic acid is used according to the invention.
• the reduction to the diol 6 is also carried out under standard conditions, using for example sodium borohydride as reducing agent.
• sodium borohydride as reducing agent, the 7,8-trans-diol indicated is obtained in over 90% diastereomeric purity.
• the subsequent etherification which is carried out according to known processes, e.g. as described in the Examples, leads to the final products of formula 1* in which R2a and R3b are hydrogen.
• the aldol condensation with benzaldehyde is carried out under standard conditions.
• the epoxidation is also carried out in a manner known per se, using preferably hydrogen peroxide as oxidant under basic conditions.
• the substances according to the invention are isolated and purified in a manner known per se, for example, by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example, column chromatography on suitable support material.
• Salts are obtained by dissolving the free compound in a suitable solvent, e.g. in a chlorinated hydrocarbon, such as dichloromethane or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol) which contains the desired acid, or to which the desired acid is subsequently added.
• a suitable solvent e.g. in a chlorinated hydrocarbon, such as dichloromethane or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol) which contains the desired acid, or to which the desired acid is subsequently added.
• the salts are obtained by filtering, reprecipitating, precipitating with a nonsolvent for the addition salt or by evaporating the solvent.
• Salts obtained can be converted by alkalization or by acidification into the free compounds, which in turn can be converted into salts. In this way, pharmacologically intolerable salts can be converted into pharmacologically tolerable salts.
• the pure enantiomers in particular the pure enantiomers of the formula 1*, to which the invention preferably relates, can be obtained in a manner familiar to the person skilled in the art, for example by using pure enantiomers of the intermediates, by enantioselective synthesis (see, for example, the Schemes), by chromatographic separation on chiral separating columns, by derivatization with chiral auxiliary reagents, subsequent separation of diastereomers and removal of the chiral auxiliary group, by salt formation with chiral acids, subsequent separation of the salts and liberation of the desired compound from the salt, or by (fractional) crystallization from a suitable solvent.
• Trans-products obtained can be converted (at least partly) to the corresponding cis-products (with R2b and R3b hydrogen) by standing under acidic conditions (e.g. 2 equivalents of acid, such as sulfuric acid) in the corresponding alcohol R2a-OH.
• acidic conditions e.g. 2 equivalents of acid, such as sulfuric acid
• cis-products obtained can be converted to the corresponding trans-products.
• the cis- and trans-products are separated e.g. by chromatography or by crystallization.
• the reaction is stirred for 2 h between ⁇ 70 to ⁇ 60° C. and warmed up to 25° C. and stirred 4 h again.
• the reaction is quenched by adding of saturated aqueous ammonium chloride solution (2.0 ml). Subsequently the mixture is concentrated in vacuo.
• the crude mixture is dissolved in dichlormethane and washed with saturated aqueous ammonium chloride solution, dried over sodium sulphate and evaporated in vacuo.
• the crude product is purified by crystallisation (i-propanol) to give the title compound as a light yellow solid 23.50 g (63.80 mmol/53%) with a melting point of 195° C. (i-propanol).
• the crude product is purified by column chromatography (diethylether/dichloromethane 8:2) to give the title compound as a light yellow solid (0.26 g, 0.77 mmol/57%) with a melting point of 204° C. (diethylether/dichloromethane).
• the crude product is purified by chromatography (diethyl ether/cyclohexane: 8/2) to provide the desired compound as a colourless solid (1.20 g, 2.83 mmol/37%) with a melting point of 213° C. (diethyl ether/cyclohexane).
• the crude product is purified by chromatography (diethyl ether/cyclohexane: 8/2) to give the title compound as a light yellow solid (0.22 g, 0.52 mmol/88%) with a melting point of 223° C. (diethyl ether/cyclohexane).
• the compounds of the formula 1 and their salts have useful pharmacological properties which make them commercially utilizable. In particular, they exhibit a marked inhibition of gastric acid secretion and an excellent gastric and intestinal protective action in warm-blooded animals, in particular humans.
• the compounds according to the invention are distinguished by a high selectivity of action, an advantageous duration of action, a particularly good enteral activity, the absence of significant side effects and a large therapeutic breadth.
• Gastric and intestinal protection in this connection is understood as meaning the prevention and treatment of gastrointestinal diseases, in particular of gastrointestinal inflammatory diseases and lesions, and of gastric acid-related diseases in mammals including man (such as, for example, gastric ulcers, duodenal ulcers, gastritis, hyperacidic. or medicament-related functional gastropathy, reflux esophagitis, Zollinger-Ellison syndrome, heartburn), which can be caused, for example, by microorganisms (e.g. Helicobacter pylori ), bacterial toxins, medicaments (e.g. certain antiinflammatories and antirheumatics), chemicals (e.g. ethanol), gastric acid or stress situations.
• microorganisms e.g. Helicobacter pylori
• bacterial toxins e.g. certain antiinflammatories and antirheumatics
• chemicals e.g. ethanol
• the compounds according to the invention surprisingly prove to be clearly superior to the compounds known from the prior art in various models in which the antiulcerogenic and the antisecretory properties are determined.
• the compounds of the formula 1 and their pharmacologically tolerable salts are outstandingly suitable for use in human and veterinary medicine, where they are used, in particular, for the treatment and/or prophylaxis of disorders of the stomach and/or intestine.
• the invention therefore further relates to the compounds according to the invention for use in the treatment and/or prophylaxis of the abovementioned diseases.
• the Invention likewise comprises the use of the compounds according to the Invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the abovementioned diseases.
• the invention furthermore comprises the use of the compounds according to the invention for the treatment and/or prophylaxis of the abovementioned diseases.
• the invention furthermore relates to medicaments which contain one or more compounds of the formula 1 and/or their pharmacologically tolerable salts.
• the medicaments are prepared by processes known per se, which are familiar to the person skilled in the art.
• suitable pharmaceutical auxiliaries or excipients in the form of tablets, coated tablets, capsules, suppositories, patches (e.g. as TTS), emulsions, suspensions or solutions, where the active compound content is advantageously between 0.1 and 95% and where, by the appropriate choice of
• auxiliaries or excipients which are suitable for the desired pharmaceutical formulations.
• Beside solvents, gel-forming agents, suppository bases, tablet auxiliaries and other active compound carriers it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers, colorants or, in particular, permeation promoters and complexing agents (e.g. cyclodextrins).
• the active compounds can be administered orally, parenterally or percutaneously.
• the pharmaceutical preparations can also contain one or more pharmacologically active constituents of other pharmaceutical groups.
• tranquilizers for example from the benzodiazapines group, e.g. diazepam
• spasmolytics e.g. bietamiverine or camylofin
• anticholinergics e.g. oxyphencyclimine or phencarbamide
• local anesthetics e.g. tetracaine or procaine
• enzymes for example from the benzodiazapines group, e.g. diazepam
• spasmolytics e.g. bietamiverine or camylofin
• anticholinergics e.g. oxyphencyclimine or phencarbamide
• local anesthetics e.g. tetracaine or procaine
• enzymes e.g. tetracaine or procaine
• H2 blockers e.g. cimetidine, ranitidine
• H+/K+-ATPase inhibitors e.g. omeprazole, pantoprazole
• peripheral anticholinergics e.g. pirenzepine, telenzepine
• gastrin antagonists with the aim of increasing the main action in an additive or superadditive sense and/or of eliminating or decreasing the side effects, or furthermore the combination with antibacterially active substances (e.g.
• cephalosporins cephalosporins, tetracyclines, penicillins, macrolides, nitroimidazoles or alternatively bismuth salts
• Antibacterially active combination components which may be mentioned are, for example, meziocillin, ampicillin, amoxycillin, cefalothin, cefoxitin, cefotaxime, imipenem, gentamycin, amikacin, erythromycin, ciprofloxacin, metronidazole, clarithromycin, azithromycin and combinations thereof (e.g. clarithromycin+metronidazole).
• Table A shows the effects of the compounds according to the invention on the pentagastrin-stimulated acid secretion of the perfused rat stomach in vivo after intravenous administration. TABLE A Dose Inhibition of acid No. ( ⁇ mol/kg) i.v. secretion (%) 1 1 100 3 1 100
• the substances to be tested were administered intravenously in 1 ml/kg liquid volumes 60 min after the start of the pentagastrin continuous infusion.
• the body temperature of the animals was kept at a constant 37.8-38° C. by infrared irradiation and heat pads (automatic, stepless control by means of a rectal temperature sensor).

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=8168269

Family Applications (2)

Family Applications After (1)

Country Status (22)

Cited By (1)

Families Citing this family (9)

Family Cites Families (4)

• 2001
  • 2001-03-28 AU AU56228/01A patent/AU784611B2/en not_active Ceased
  • 2001-03-28 CA CA002404466A patent/CA2404466A1/en not_active Abandoned
  • 2001-03-28 NZ NZ520836A patent/NZ520836A/en unknown
  • 2001-03-28 HR HRP20020855 patent/HRP20020855A2/hr not_active Application Discontinuation
  • 2001-03-28 HU HU0300569A patent/HUP0300569A3/hu unknown
  • 2001-03-28 CN CNB01807166XA patent/CN1221554C/zh not_active Expired - Fee Related
  • 2001-03-28 AT AT01929463T patent/ATE381568T1/de not_active IP Right Cessation
  • 2001-03-28 WO PCT/EP2001/003510 patent/WO2001072755A1/en not_active Ceased
  • 2001-03-28 PL PL01365824A patent/PL365824A1/xx unknown
  • 2001-03-28 US US10/182,620 patent/US20030100578A1/en not_active Abandoned
  • 2001-03-28 EA EA200200883A patent/EA006095B1/ru not_active IP Right Cessation
  • 2001-03-28 BR BR0109589-7A patent/BR0109589A/pt not_active Application Discontinuation
  • 2001-03-28 EP EP01929463A patent/EP1286999B1/de not_active Expired - Lifetime
  • 2001-03-28 KR KR1020027012691A patent/KR20020082494A/ko not_active Abandoned
  • 2001-03-28 CZ CZ20023210A patent/CZ20023210A3/cs unknown
  • 2001-03-28 ES ES01929463T patent/ES2298233T3/es not_active Expired - Lifetime
  • 2001-03-28 SK SK1386-2002A patent/SK13862002A3/sk unknown
  • 2001-03-28 DE DE60131968T patent/DE60131968T2/de not_active Expired - Fee Related
  • 2001-03-28 JP JP2001570664A patent/JP2003528877A/ja not_active Withdrawn
  • 2001-03-28 MX MXPA02009550A patent/MXPA02009550A/es active IP Right Grant
• 2002
  • 2002-09-23 ZA ZA200207635A patent/ZA200207635B/en unknown
  • 2002-09-24 NO NO20024572A patent/NO20024572D0/no not_active Application Discontinuation
• 2004
  • 2004-04-01 US US10/811,496 patent/US6936623B2/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events